During this webinar, Lumere experts Samantha Bastow, PharmD, and Grace Fox, PhD, highlight the evidence associated with Sugammadex for reversal of neuromuscular blockade during surgery. Key takeaways include:
- Sugammadex has been shown to decrease time to recovery and residual neuromuscular blockade compared to neostigmine and glycopyrrolate.
- The clinical and operational significance of existing evidence should be determined based on institution-specific factors to determine place on formulary.
- Restrictions should be proactively identified and compliance (restriction criteria and appropriate dosing) should be reviewed and reported at a regular cadence.